This is a working overview of Lactam bridge, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Reverse-phase high-performance liquid chromatography is the standard method for assessing purity. Mass spectrometry confirms molecular identity and detects sequence variants or truncation products. Ultraviolet absorbance at 214 or 280 nm is used for quantification, with the choice depending on the peptide sequence. Method validation typically addresses linearity, limit of detection, and precision across a defined concentration range. Impurity profiling may also employ ion-exchange or size-exclusion chromatography, and these techniques complement one another.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
The convoy scattered, and Gaddafi and those closest to him fled to a nearby villa, which was shelled by rebel militia from Misrata. Fleeing to a construction site, Gaddafi and his inner cohort hid inside drainage pipes while his bodyguards battled the rebels; in the conflict, Gaddafi suffered head injuries from a grenade blast while Jabr was killed. The Misrata militia took Gaddafi prisoner, causing serious injuries as they tried to apprehend him; the events were filmed on a mobile phone. A video appears to picture Gaddafi being poked or stabbed in the anus "with some kind of stick or knife" or possibly a bayonet. Pulled onto the front of a pick-up truck, he fell off as it drove away. His semi-naked body was then placed into an ambulance and taken to Misrata; upon arrival, he was found to be dead. Official NTC accounts claimed that Gaddafi was caught in a crossfire and died from bullet wounds. Other eye-witness accounts claimed that rebels had fatally shot Gaddafi in the stomach. That afternoon, NTC Prime Minister Mahmoud Jibril publicly revealed the news of Gaddafi's death. His corpse was placed in the freezer of a local market alongside the corpses of Yunis Jabr and Mutassim; the bodies were publicly displayed for four days, with Libyans from all over the country coming to view them. Footage of Gaddafi's death was broadcast extensively across media networks internationally. In response to international calls, on 24 October Jibril announced that a commission would investigate Gaddafi's death.
Hart (1874–1953), American biochemist at the University of Wisconsin-Madison who studied farm animal diet. Brian S. Hartley FRS (1926–2021). British biochemist at Imperial College London. Known for studies on chymotrypsin and other proteolytic enzymes. Hamilton Hartridge FRS (1886–1976). British eye physiologist known in biochemistry for the continuous-flow method for following fast reactions. Demis Hassabis (b. 1976). British computer scientist and artificial intelligence researcher at University College London. Nobel Prize in chemistry 2024. Reinhart Heinrich (1946–2006). German biophysicist at the Humboldt University of Berlin, noted for the origin and development of metabolic control analysis. Max Henius (1859–1935). Danish-American biochemist who specialized in fermentation processes. Founder of the Chicago-based American Brewing Academy. Victor Henri (1872–1940). French physical chemist of Russian parents at the University of Liège. He was the first to apply ideas of physical chemistry to the properties of enzymes. Avram Hershko (b. 1937 as Herskó Ferenc). Hungarian-Israeli biochemist at the Technion (Haifa), known for the discovery of ubiquitin-mediated protein degradation. Nobel Prize in Chemistry (2004). Foreign associate Natl. Acad. Sci. USA.
Sydney Harbour A unit of volume used in Australia for water. One Sydney Harbour is the amount of water in Sydney Harbour: approximately 562 gigalitres (562,000,000 cubic metres, or 0.562 cubic kilometres); or in terms of the more unusual measures above, about 357 Melbourne Cricket Grounds, 238,000 Olympic Swimming pools, or 476,000 acre-feet. The Grand Canyon With a volume measure approximately 4 orders of magnitude greater than Sydney Harbour, the volume of the Grand Canyon may be used to visualize even larger things, like the magma chamber underneath Yellowstone and other things. According to the National Park Service, the volume of the Grand Canyon is 4.17 trillion cubic metres (5.45 trillion cubic yards) which is 4,170 km3 (1,000 mi3).
In cases where the patients with anorexia nervosa continually refuse significant dietary intake and weight restoration interventions, a psychiatrist can declare the patient to lack capacity to make decisions, which results in a medical decision to be fed by restraint via nasogastric tube. Anorexia often develops during adolescence or young adulthood. The causes of anorexia nervosa are complex and vary across individuals, many of which can include genetic, societal, physiological, and environmental causes. Most commonly, the exacerbation of the mental illness is thought to follow a major life-change or stress-inducing events. There is strong evidence, however, that anorexia nervosa also has a genetic component, with identical twins being affected more often than fraternal twins, which sees a large number of genetic risk factors underlying the disorder: similar to other psychiatric disorders with genetic components. Cultural factors also play a very significant role, with societies that value thinness having higher rates of the disease. Anorexia nervosa also commonly occurs in athletes who play sports where a low bodyweight is thought to be advantageous for aesthetics or performance, such as dance, cheerleading, gymnastics, running, figure skating and ski jumping (anorexia athletica).
On 7 April (8 April in Iran and Israel), Trump announced that he agreed to a two-week ceasefire with Iran and the proposal by Pakistan, stating that Iran would immediately open the Strait of Hormuz and work on finalizing a peace agreement. Later on the same day, Abbas Araghchi announced that Iran had agreed to the conditions. Iran claimed victory, asserting that it had forced the US to accept its 10-point plan, which includes lifting all sanctions on Iran and withdrawing all US forces from all bases in the region. Trump said the Iranian 10 point proposal was a "workable basis on which to negotiate". Hezbollah announced a pause in attacks against Israel, according to the ceasefire. Israel has also agreed to the temporary ceasefire. According to Pakistani Prime Minister Shehbaz Sharif, the ceasefire includes all fronts of the war, including Lebanon. Israeli Prime Minister Benjamin Netanyahu rejected Sharif's inclusion of Lebanon, asserting that the ceasefire "does not include Lebanon", an assertion backed by Trump and Vance. Hezbollah said that it halted attacks on Israel and on Israeli soldiers in Lebanon. A few hours later Israel launched the strongest wave of attacks on Lebanon since the start of the war. In response, Iranian media later said that Iran paused Hormuz traffic over Israeli attacks in Lebanon. The Lebanese government denounced what occurred as a war crime. The IRGC warned of a 'regretful response' if the attacks on Lebanon do not stop.
Sources: en.wikipedia.org
Additionally, arsenic trioxide degrades poly(ADP-ribose) polymerase, which, combined with the activation of caspases, inhibits DNA repair and halts the cell cycle. The phase of the cell cycle at which the blockage occurs primarily depends on the p53 protein. In cells containing the so-called "wild type" (non-mutated) p53, the cell cycle is halted in the interphase, while in cells with mutated p53, it is halted in the G2/M phase.
== Function == Fibromodulin participates in the assembly of the collagen fibers of the extracellular matrix. It binds to the same site on the collagen type I molecule as lumican. It also inhibits fibrillogenesis of collagen type I and collagen type III in vitro. It regulates TGF-beta activities by sequestering TGF-beta into the extracellular matrix.
In plants, ATP synthase is also present in chloroplasts (CF1FO-ATP synthase). The enzyme is integrated into thylakoid membrane; the CF1-part sticks into stroma, where dark reactions of photosynthesis (also called the light-independent reactions or the Calvin cycle) and ATP synthesis take place. The overall structure and the catalytic mechanism of the chloroplast ATP synthase are almost the same as those of the bacterial enzyme. However, in chloroplasts, the proton motive force is generated not by respiratory electron transport chain but by primary photosynthetic proteins. The synthase has a 40-aa insert in the gamma-subunit to inhibit wasteful activity when dark. CF1FO-ATP synthase is less efficient to its mitochondrial counterpart and exchanges 4—4.67 protons per ATP.
Extrapituitary prolactin is controlled by a superdistal promoter, located 5.8 kb upstream of the pituitary start site. The promoter does not react to dopamine, estrogens, or TRH. Instead, it is stimulated by cAMP. Responsiveness to cAMP is mediated by an imperfect cAMP–responsive element and two CAAT/enhancer binding proteins (C/EBP). Progesterone upregulates prolactin synthesis in the endometrium but decreases it in myometrium and breast glandular tissue. Breast and other tissues may express the Pit-1 promoter in addition to the distal promoter. Oct-1 appears able to substitute for Pit-1 in activating the promoter in breast cancer cells. Extrapituitary production of prolactin is thought to be special to humans and primates and may serve mostly tissue-specific paracrine and autocrine purposes. It has been hypothesized that in vertebrates such as mice a similar tissue-specific effect is achieved by a large family of prolactin-like proteins controlled by at least 26 paralogous PRL genes not present in primates.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.